Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
172
-
Total 13F shares, excl. options
-
91.7M
-
Shares change
-
+5.93M
-
Total reported value, excl. options
-
$836M
-
Value change
-
+$16.2M
-
Put/Call ratio
-
0.66
-
Number of buys
-
99
-
Number of sells
-
-68
-
Price
-
$9.11
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q1 2022
207 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q1 2022.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.7M shares
of 226M outstanding shares and own 40.52% of the company stock.
Largest 10 shareholders include TPG GP A, LLC (18.7M shares), STATE STREET CORP (7.88M shares), BlackRock Inc. (7.09M shares), VANGUARD GROUP INC (6.75M shares), PRIMECAP MANAGEMENT CO/CA/ (4.91M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.27M shares), JPMORGAN CHASE & CO (3.56M shares), GOLDMAN SACHS GROUP INC (2.96M shares), CITADEL ADVISORS LLC (2.62M shares), and Wildcat Capital Management, LLC (2.13M shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.